World's Best Scientists 2026 revealed!
Jonathan E. Kolitz

Jonathan E. Kolitz

D-Index & Metrics

Medicine

D-Index
85
Citations
36192
World Ranking
14408
National Ranking
7287

Overview

Jonathan E. Kolitz is affiliated with Hofstra University in the United States. Their research primarily focuses on hematology and molecular biology, with significant contributions to the study of acute myeloid leukemia (AML) and related hematologic malignancies.

The scientist has authored numerous papers, with several notable recent publications including:

  • CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial (2021), published in The Lancet Haematology
  • Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A (2020), published in Proceedings of the National Academy of Sciences
  • Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years (2020), published in Leukemia
  • Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia (2020), published in Cancer Discovery
  • Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801 (2020), published in Blood Advances

Frequent collaborators in their work include:

  • Krzysztof Mrózek
  • Bayard L. Powell
  • Deedra Nicolet
  • Richard M. Stone
  • Ann-Kathrin Eisfeld

Jonathan E. Kolitz's publications are often found in journals specialized in hematology and oncology. The most common publication venues include:

  • Blood
  • Leukemia
  • Blood Advances
  • Journal of Clinical Oncology
  • Journal of Hematology & Oncology

Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on subfields such as Hematology, Molecular Biology, Genetics, Public Health, Environmental and Occupational Health, and Immunology.

The scientist's primary research topics cover:

  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments

Best Publications

  • Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

    Rajendra N. Damle;Tarun Wasil;Tarun Wasil;Tarun Wasil;Franco Fais;Franco Fais;Franco Fais;Fabio Ghiotto;Fabio Ghiotto;Fabio Ghiotto

  • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

    Kanti R. Rai;Bercedis L. Peterson;Frederick R. Appelbaum;Jonathan Kolitz

  • CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

    Jeffrey E. Lancet;Geoffrey L. Uy;Jorge E. Cortes;Laura F. Newell

  • IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  • Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study

    Susan P. Whitman;Kellie J. Archer;Lan Feng;Claudia Baldus

  • Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study

    Peter Paschka;Guido Marcucci;Amy S. Ruppert;Krzysztof Mrózek

  • In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

    Bradley T. Messmer;Davorka Messmer;Steven L. Allen;Steven L. Allen;Jonathan E. Kolitz;Jonathan E. Kolitz

  • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

    John C. Byrd;Kanti Rai;Bercedis L. Peterson;Frederick R. Appelbaum

  • B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes.

    Rajendra N. Damle;Fabio Ghiotto;Angelo Valetto;Emilia Albesiano

  • Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

    E Berman;G Heller;J Santorsa;S McKenzie

  • Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

    Bradley T. Messmer;Emilia Albesiano;Dimitar G. Efremov;Fabio Ghiotto;Fabio Ghiotto

  • MicroRNA expression in cytogenetically normal acute myeloid leukemia

    Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek

  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

    Maria R. Baer;Stephen L. George;Richard K. Dodge;Kieran L. O'Loughlin

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

    Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  • Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

    Guido Marcucci;Krzysztof Mrózek;Amy S. Ruppert;Kati Maharry

  • Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

    Eric J. Feldman;Jeffrey E. Lancet;Jonathan E. Kolitz;Ellen K. Ritchie

  • Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

    Jeffrey E. Lancet;Jorge E. Cortes;Donna E. Hogge;Martin S. Tallman

Frequent Co-Authors

Kanti R. Rai
Kanti R. Rai Hofstra University
Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Bayard L. Powell
Bayard L. Powell Wake Forest University
Nicholas Chiorazzi
Nicholas Chiorazzi Feinstein Institute for Medical Research
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Richard Stone
Richard Stone Harvard University
Richard A. Larson
Richard A. Larson University of Chicago
Andrew J. Carroll
Andrew J. Carroll University of Alabama at Birmingham
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in exploring other healthcare and medicine-related fields? Online degree programs offer diverse and flexible pathways to support your ambitions, whether you are starting your journey or advancing your career.

If you want to help patients improve their diet and overall health, a nutrition degree online can open doors to roles in public health, wellness, and food industries. For those aspiring to move into healthcare leadership, the best online mha programs provide knowledge in management, policy, and system-based healthcare challenges.

Registered nurses hoping to advance quickly may benefit from online rn to bsn programs without clinical requirements, allowing them to upgrade credentials with added flexibility. For experienced nurses and healthcare professionals, dnp programs online offer an efficient route to doctoral-level leadership and practice roles.

Online programs make it easier to balance your education with professional and personal commitments, making healthcare degrees more accessible than ever.

Best Scientists Citing Jonathan E. Kolitz

Trending Scientists

Recently Published Articles